ANIX
Anixa Biosciences, Inc.
There isn't enough reported data to score ANIX yet.
ANIX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
ANIX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
ANIX PE Valuation
ANIX has no meaningful PE right now: it lost money over the past year.
ANIX Forward outlook
There aren't enough analyst estimates for ANIX to show an outlook.
ANIX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$0.34 | +$0.14 |
| Q2 2023 | -$0.35 | +$0.18 |
| Q1 2023 | -$0.40 | +$0.09 |
| Q4 2022 | -$0.45 | $0.00 |
| Q3 2022 | -$0.48 | -$0.08 |
| Q2 2022 | -$0.53 | -$0.16 |
| Q1 2022 | -$0.49 | -$0.08 |
| Q4 2021 | -$0.45 | $0.00 |
ANIX is still losing money, but less than at its worst: $0.31 per share over the past year, against $0.59 at its worst in late 2019.
ANIX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2022 | $513K | +0.1% |
ANIX's revenue has slid since its 2022 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2023 | -1219% | N/A |
| Q1 2022 | -756% | -321 points |
| Q1 2021 | -436% | N/A |
ANIX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.8M | -$259K |
| Q2 2026 | -$1.7M | -$238K |
| Q1 2026 | -$2.6M | +$294K |
| Q4 2025 | -$1.3M | -$328K |
| Q3 2025 | -$1.5M | +$1.1M |
| Q2 2025 | -$1.5M | -$47K |
| Q1 2025 | -$2.9M | -$595K |
| Q4 2024 | -$927K | +$1M |
ANIX has burned cash in almost every quarter: −$7M over the past year, against −$7M the year before.
ANIX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +589K shares |
| 1 year | +6.1% | +2M shares |
| 3 years | +36% | +9M shares |
ANIX has 34M diluted shares, up 6.1% from a year ago.
ANIX Net Leverage
ANIX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ANIX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.8 | Neutral |
| Stochastic | 33.0 | Neutral |
ANIX's weekly RSI is 44 (neutral) and its Stochastic is 33 (neutral).
ANIX PE vs Healthcare Sector
ANIX has no meaningful PE right now: it lost money over the past year.
ANIX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.91 | 7.9% below |
| 20 week MA | $3.13 | 14% below |
| 50 week MA | $3.04 | 12% below |
| 100 week MA | $3.09 | 13% below |
| 200 week MA | $3.30 | 19% below |
ANIX is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ANIX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.89 | $2.85 | -1.4% |
| 2021 | $2.85 | $3.18 | +12% |
| 2022 | $3.18 | $3.94 | +24% |
| 2023 | $3.94 | $3.88 | -1.5% |
| 2024 | $3.88 | $2.56 | -34% |
| 2025 | $2.56 | $3.20 | +25% |
| 2026 YTD | $3.20 | $2.68 | -16% |
ANIX has finished lower in three of the last six years. It's down 16% so far in 2026.